Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06980948 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 11 sitesv8
  2. Study sites: 10 to 11
    • Start date changed from estimate of Oct 2025 to Dec 4, 2025
    • Eligibility criteria shortened, about 837 words
    • Study description expanded, about 1 word
    v7
  3. Phase: Phase 1 to Phase 1/2v6 Show 5 more changesShow less
    • Eligibility criteria expanded, about 803 words
    • Secondary endpoints revised (11)
    • Study description shortened, about 23 words
    • Site details revised at 1 of 10 sites
    • Study title expanded, about 5 words
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 9 to 10
    v5
  5. Start date: Jul 2025 to Oct 2025
    • Study sites: 8 to 9
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 7 to 8v3
  2. Study sites: 5 to 7v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
Trial Details
NCT Number NCT06980948
Lead Sponsor Sangamo Therapeutics
Conditions
(from sponsor)		 Chronic Neuropathic Pain
Related terms Small Fiber Neuropathy
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov